Lectures and seminars OnkPat Friday Seminar: Multi-omics uncovers factors associated with resistance to osimertinib in EGFR-mutant non-small cell lung cancer

Host: Kasper Karlsson, Department of Oncology-Pathology

About Per Hydbring

Docent Per Hydbring is a molecular biologist with a focus on experimental oncology. He conducted his PhD on studying the role of MYC in suppressing senescence in transformation followed by post-doctoral studies on targeting the cell cycle machinery through therapeutic RNAs. As a principal investigator, he is focused on finding new therapeutic tools in lung cancer, with a particular focus on advanced lung cancer disease progressing on standard-of-care treatments.

Selected publications

Elevated expression of miR-494-3p is associated with resistance to osimertinib in EGFR T790M-positive non-small cell lung cancer.
Kaźmierczak D, Eide IJZ, Gencheva R, Lai Y, Lewensohn R, Tsakonas G, Grundberg O, de Petris L, McGowan M, Brustugun OT, Ekman S, Hydbring P
Transl Lung Cancer Res 2022 May;11(5):722-734

An immune gene expression signature distinguishes central nervous system metastases from primary tumours in non-small-cell lung cancer.
Tsakonas G, Lewensohn R, Botling J, Ortiz-Villalon C, Micke P, Friesland S, Nord H, Lindskog M, Sandelin M, Hydbring P, Ekman S
Eur J Cancer 2020 Jun;132():24-34

miR-100-5p confers resistance to ALK tyrosine kinase inhibitors Crizotinib and Lorlatinib in EML4-ALK positive NSCLC.
Lai Y, Kacal M, Kanony M, Stukan I, Jatta K, Kis L, Norberg E, Vakifahmetoglu-Norberg H, Lewensohn R, Hydbring P, Ekman S
Biochem Biophys Res Commun 2019 Apr;511(2):260-265

Cell-Cycle-Targeting MicroRNAs as Therapeutic Tools against Refractory Cancers.
Hydbring P, Wang Y, Fassl A, Li X, Matia V, Otto T, Choi YJ, Sweeney KE, Suski JM, Yin H, Bogorad RL, Goel S, Yuzugullu H, Kauffman KJ, Yang J, Jin C, Li Y, Floris D, Swanson R, Ng K, Sicinska E, Anders L, Zhao JJ, Polyak K, Anderson DG, Li C, Sicinski P
Cancer Cell 2017 Apr;31(4):576-590.e8